Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature
- PMID: 40889102
- DOI: 10.1007/s13304-025-02382-z
Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature
Abstract
Long-term survivors after pancreatic resection for PDAC are rare, constituting a specific subset of patients that remains poorly understood. This study aims to identify the clinic-pathological, molecular, and therapeutic factors for predicting long-term survival (LTS). A systematic review and random-effect meta-analysis were conducted. Inclusion criteria were PDAC histology, resected patients, studies reporting risk factors, and comparing two groups. The primary endpoint was to evaluate predictive factors for LTS in patients with PDAC who underwent surgery. Results were reported with the Mantel-Haenszel random effects model using Risk Ratio (RR) or Mean Difference (MD). Meta-regression analysis was used to clarify heterogeneity. Nineteen studies, involving a total of 5412 patients, were included: 1097 (20,3%) in group LTS and 4334 (79,7%) in group STS (short-term survivors). These factors were associated to LTS: small size (RR 1.53, 95% IC 1.14; 2.05); T1-T2 stage (RR 1.07, 95% IC 1.03; 1.11); N0 (RR 1.82, 95% IC 1.60; 2.09); AJCC Stage I (RR 2.28 95% IC 1.87; 2.79); low-grade G1-2 (RR 1.21, 95% IC 1.09; 1.34); R0 resection (RR 1.11, 95% IC 1.08; 1.13); low levels of CEA (MD - 4.41, 95% IC - 6.23; - 2.59) and Ca 19.9 (MD - 66.4, 95% IC: - 71.9; - 60.9); absence of perineural invasion (RR 0.93, 95% IC: 0.90; 0.96), lymph-vascular invasion (RR 0.87, 95% IC: 0.83; 0.91), venous invasion (RR 0.63, 95% IC: 0.48; 0.83) and perioperative transfusions (RR 0.56, 95% IC: 0.40; 0.79). Several factors are associated with an LTS. They can be considered reliable indicators for predicting tumor progression.
Keywords: Long-term survival; PDAC; Pancreatectomy; Pancreatic cancer; Predictive factors.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: Authors declare they have no conflicts of interest. Registration and protocol: PROSPERO 2023 CRD42023472753. Research involving human participants and/or animals: This study is a meta-analysis based on previously published data and did not involve any direct research with human participants or animals. Therefore, ethical approval was not required. Informed consent: Informed consent was not required for this type of study.
References
-
- Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921 - PubMed
-
- Mizrahi JD, Surana R, Valle JW et al (2020) Pancreatic cancer. Lancet 395(10242):2008–2020 - PubMed
-
- Barhli A, Cros J, Bartholin L et al (2018) Prognostic stratification of resected pancreatic ductal adenocarcinoma: past, present and future. Dig Liver Dis 50(10):979–990 - PubMed
-
- Neuzillet C, Tijeras-Raballand A, Bourget P et al (2015) State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther 155:80–104 - PubMed
-
- Higgins JPTGS (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, London
Publication types
LinkOut - more resources
Full Text Sources
